KPTI News and Press, Karyopharm Therapeutics Inc. From 11/02/23

2023-11-02 07:33:14 ET More on Karyopharm Therapeutics Karyopharm Therapeutics: Seeking Upside Potential But Catalysts Too Far Away Karyopharm Therapeutics Q3 2023 Earnings Preview Karyopharm, Bristol Myers to evaluate drug combination for treatment of multiple myelo...

Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress PR Newswire – Achieved Third Quarter 2023 Total Revenue of $36.0 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $30.2 Million – ȁ...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

Karyopharm Therapeutics Inc. (KPTI) is expected to report $-0.28 for Q3 2023

2023-11-01 13:57:55 ET More on Karyopharm Therapeutics Karyopharm Therapeutics: Seeking Upside Potential But Catalysts Too Far Away Karyopharm, Bristol Myers to evaluate drug combination for treatment of multiple myeloma Seeking Alpha’s Quant Rating on Karyoph...

Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma PR Newswire — Phase 1b /2 Trial Will Investig...

Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023 PR Newswire -- Conference Call Scheduled for Thursday, November 2, 2023 , at 8:00 a.m. ET -- NEWTON, Mass. , Oct. 26, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (...

Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings PR Newswire NEWTON, Mass. , Sept. 26, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq...

Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors PR Newswire NEWTON, Mass. , Sept. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the ...

2023-08-21 03:07:26 ET Summary Karyopharm Therapeutics reported $37.6 million in total revenue, with a net loss of $32.6 million. The company holds $80.9 million in cash and equivalents, as well as $156 million in investments. KPTI has a commercialized drug and potential for g...